Anti-PD-1 immunotherapy with adjuvant ablative fractional laser displays increased tumour clearance of squamous cell carcinoma, a murine study.
PD-1 inhibitors
ablative fractional laser
cancer immunotherapy
immune checkpoint inhibitor
keratinocyte carcinoma
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
06
12
2023
received:
15
06
2023
accepted:
28
12
2023
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
28
2
2024
Statut:
ppublish
Résumé
PD-1 checkpoint inhibitors are used as systemic immunotherapy for locally advanced and metastatic cutaneous squamous cell carcinoma (SCC); however, improved treatment efficacy is urgently needed. In this study, we aimed to investigate the effect of combining systemic anti-PD-1 treatment with adjuvant ablative fractional laser (AFL) in a spontaneous SCC mouse model. Tumours induced by ultraviolet radiation in the strain C3.Cg-Hr
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15013Subventions
Organisme : Greater Copenhagen Health Science Partners
Organisme : Fabrikant Vilhelm Pedersen og Hustrus Legat
ID : 0052695
Organisme : LEO Fondet
ID : LF18045
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151(10):1081-1086. doi:10.1001/jamadermatol.2015.1187
Leiter U, Keim U, Garbe C. Epidemiology of skin cancer: update 2019. In Reichrath J, ed. Sunlight, vitamin D and skin cancer. Advances in experimental medicine and biology. Springer International Publishing; 2020:123-139.
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-1080. doi:10.1111/j.1365-2133.2012.10830.x
Mendez BM, Thornton JF. Current basal and squamous cell skin cancer management. Plast Reconstr Surg. 2018;142(3):373e-387e. doi:10.1097/PRS.0000000000004696
Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153. doi:10.1136/bmj.f6153
Patel R, Chang ALS. Immune checkpoint inhibitors for treating advanced cutaneous squamous cell carcinoma. Am J Clin Dermatol. 2019;20(4):477-482. doi:10.1007/s40257-019-00426-w
Lee A, Duggan S, Deeks ED. Cemiplimab: a review in advanced cutaneous squamous cell carcinoma. Drugs. 2020;80(8):813-819. doi:10.1007/s40265-020-01302-2
Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancer. 2020;12(3):738. doi:10.3390/cancers12030738
Markham A, Duggan S. Cemiplimab: First Global Approval. Drugs. 2018;78(17):1841-1846. doi:10.1007/s40265-018-1012-5
Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-351. doi:10.1056/NEJMoa1805131
Lai C, August S, Albibas A, et al. OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T cell responses and associate with metastatic potential. Clin Cancer Res. 2016;22(16):4236-4248. doi:10.1158/1078-0432.CCR-15-2614
Lai C, Coltart G, Shapanis A, et al. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma. J Immunother Cancer. 2021;9(1):e001807. doi:10.1136/jitc-2020-001807
Li Y, Liu J, Gao L, et al. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. Immunol Lett. 2020;220:88-96. doi:10.1016/j.imlet.2019.03.006
Vidovic D, Simms GA, Pasternak S, et al. Case report: combined intra-Lesional IL-2 and topical imiquimod safely and effectively clears multi-focal, high grade cutaneous squamous cell cancer in a combined liver and kidney transplant patient. Front Immunol. 2021;12:678028. doi:10.3389/fimmu.2021.678028
Kawakubo M, Demehri S, Manstein D. Fractional laser exposure induces neutrophil infiltration (N1 phenotype) into the tumor and stimulates systemic anti-tumor immune response. PLoS One. 2017;12(9):e0184852. doi:10.1371/journal.pone.0184852
Kawakubo M, Cunningham TJ, Demehri S, Manstein D. Fractional laser releases tumor-associated antigens in poorly immunogenic tumor and induces systemic immunity. Sci Rep. 2017;7(1):12751. doi:10.1038/s41598-017-13095-8
Lo JA, Kawakubo M, Juneja VR, et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021;13(581):eabd8636. doi:10.1126/scitranslmed.abd8636
Olesen UH, Wiinberg M, Lerche CM, Jaehger DE, Andresen TL, Haedersdal M. Anti-PD-1 therapy with adjuvant ablative fractional laser improves anti-tumor response in basal cell carcinomas. Cancer. 2021;13(24):6326. doi:10.3390/cancers13246326
Fontenete S, Lerche CM, Paasch U, Perez-Moreno M, Olesen UH, Haedersdal M. Tumor clearance and immune cell recruitment in UV-induced murine squamous cell carcinoma exposed to ablative fractional laser and imiquimod treatment. Lasers Surg Med. 2021;53(9):1227-1237. doi:10.1002/lsm.23406
Lerche CM, Al-Chaer RN, Wulf HC. Does systemic hydrochlorothiazide increase the risk of developing ultraviolet radiation-induced skin tumours in hairless mice? Exp Dermatol. 2023;32(4):341-347. doi:10.1111/exd.14703
Sabbatino F, Marra A, Liguori L, et al. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. J Immunother Cancer. 2018;6(1):126. doi:10.1186/s40425-018-0439-2
Walter A, Barysch MJ, Behnke S, et al. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res. 2010;16(14):3562-3570. doi:10.1158/1078-0432.CCR-09-3136
Omland SH, Ejlertsen JS, Krustrup D, et al. Feasibility of Intratumoral anti-PD1 as treatment of human basal cell carcinoma: an explorative study with adjuvant ablative fractional laser. Cancer. 2022;14(23):5815. doi:10.3390/cancers14235815
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501. doi:10.1056/NEJMc1713444
Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129. doi:10.1186/s12943-018-0864-3
Amôr NG, da Santos PS, Campanelli AP. The tumor microenvironment in SCC: mechanisms and therapeutic opportunities. Front Cell Dev Biol. 2021;9:636544. doi:10.3389/fcell.2021.636544
Belai EB, de Oliveira CE, Gasparoto TH, et al. PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis. 2014;35(2):424-431. doi:10.1093/carcin/bgt305
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571. doi:10.1038/nature13954
Dammeijer F, van Gulijk M, Mulder EE, et al. The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020;38(5):685-700.e8. doi:10.1016/j.ccell.2020.09.001
Fransen MF, Schoonderwoerd M, Knopf P, et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight. 2018;3(23):e124507. doi:10.1172/jci.insight.124507
Nagasaki J, Inozume T, Sax N, et al. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Cell Rep. 2022;38(5):110331. doi:10.1016/j.celrep.2022.110331
Regeneron Pharmaceuticals. Libtayo (cemiplimab). US Prescribing Information. 2018. Published 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf
Owonikoko TK, Papadopoulos KP, Johnson ML, et al. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): longer follow-up efficacy and safety data. Ann Oncol. 2018;29:x25. doi:10.1093/annonc/mdy487.002
Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121(2):101-108. doi:10.1038/s41416-019-0495-5
Omland SH, Wenande EC, Svane IM, Tam J, Olesen UH, Haedersdal M. Laser immunotherapy: a potential treatment modality for keratinocyte carcinoma. Cancer. 2021;13(21):5405. doi:10.3390/cancers13215405
Helsing P, Togsverd-Bo K, Veierød MB, Mørk G, Haedersdal M. Intensified fractional CO2 laser-assisted photodynamic therapy vs. laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: a randomized half-side comparative trial on dorsal hands. Br J Dermatol. 2013;169(5):1087-1092. doi:10.1111/bjd.12507
Hibler BP, Sierra H, Cordova M, et al. Carbon dioxide laser ablation of basal cell carcinoma with visual guidance by reflectance confocal microscopy: a proof of principle pilot study. Br J Dermatol. 2016;174(6):1359-1364. doi:10.1111/bjd.14414
Campolmi P, Brazzini B, Urso C, et al. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg. 2002;28(10):909-912. doi:10.1046/j.1524-4725.2002.02076.x
Horlock N, Grobbelaar AO, Gault DT. Can the carbon dioxide laser completely ablate basal cell carcinomas? A histological study. Br J Plast Surg. 2000;53(4):286-293. doi:10.1054/bjps.1999.3277
Luo M, Shi L, Zhang F, et al. Laser immunotherapy for cutaneous squamous cell carcinoma with optimal thermal effects to enhance tumour immunogenicity. Int J Hyperth. 2018;34(8):1337-1350. doi:10.1080/02656736.2018.1446221
Murad A, William DA, Edward WC, et al. In situ photoimmunotherapy: a surgery- and limb-sparing approach to the treatment of cutaneous metastases in advanced melanoma. Arch Dermatol. 2010;146(8):831-834. doi:10.1001/archdermatol.2010.181
Li X, Naylor MF, Le H, et al. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients. Cancer Biol Ther. 2010;10(11):1081-1087. doi:10.4161/cbt.10.11.13434